ORIGINAL ARTICLE



Evaluation of immature granulocyte parameters in myeloid neoplasms assayed by Sysmex XN hematology analyzer

Qifeng Lu¹ · Ying Li² · Tian Li¹ · Tingting Hou¹ · Yajuan Zhao¹ · Shu Feng¹ · Xixian Yang¹ · Mengyu Zhu¹ · Yajuan Shen¹

Received: 5 October 2021 / Accepted: 25 January 2022 / Published online: 8 February 2022 © The Author(s) 2022, corrected publication 2024

Abstract

Immature granulocytes (IGs) have significance for the diagnosis of myeloid neoplasms (MNs). The current study aims to use a hematology analyzer to evaluate the accuracy of IG parameters in MNs. Blood specimens from 388 patients with MN, 524 with non-hematological neoplasms (non-HNs), including 109 patients with inflammation and 68 undergoing G-CSF administration, and 500 healthy control subjects were analyzed. IG parameters was assayed by Sysmex XN-9000 (XN) and compared with manual assessments. A high level of agreement between IG% derived from XN and manual measurements for MN patients (r=0.828, p < 0.0001) was revealed but only a moderate correlation for acute myeloid leukemia patients (AML; r=0.597; p < 0.0001). Bland–Altman bias analysis was conducted, and the results showed that differences in IG% from XN and manual analysis for MN patients were considered clinically insignificant. ROC analysis demonstrated a good performance of IG# (AUC=0.842) and IG% (AUC=0.885) assessed by XN for MN patients with cut-off values of $0.200 \times 10^9/L$ and 1.95%, respectively. IG parameters from Sysmex XN analyzer are helpful for screening of MNs even though granulocyte morphological abnormalities may interfere with IG parameter accuracy.

Keywords Immature granulocytes · Myeloid neoplasms · Hematology analyzer · Morphological abnormalities

Introduction

Immature granulocytes (IGs) comprise promyelocytes, myelocytes, and metamyelocytes [1]. Such cells are seldom seen in the peripheral blood (PB) of healthy subjects, except in certain physiological states and conditions, such as pregnancy or the neonatal period [2–4]. By contrast, IGs are found in patients' PB in the following pathological conditions: acute infection, inflammation, tissue injury, intravascular hemolysis, acute hemorrhage, non-hematopoietic malignant tumor, hematological neoplasms and in those receiving granulocyte colony-stimulating factor (G-CSF) or granulocyte–macrophage colony-stimulating factor

Yajuan Shen shenyajuanchina@126.com

¹ Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China

² Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China (GM-CSF) [5–13]. For patients undergoing G-CSF or GM-CSF treatment, IGs act as sensitive indices to indicate granulocytic hematopoietic recovery [12, 13]. IGs are also seen in patients with myeloid neoplasms (MNs), such as acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and their presence can be used for diagnosis. The conditions of chronic myeloid leukemia (CML) and primary myelofibrosis (PMF) are particularly associated with an increase in IG level [11].

Prior to the availability of the automated hematology analyzer, Sysmex XN series, other analyzers, including Sysmex XS, XT, and XE series, were used to sort cells for research purposes [6, 14]. The Sysmex XN analyzer uses one of the six white blood cell (WBC) differential parameters in the WBC differential (WDF) channel to sort IGs. Erythrocytes are lysed by lysercell WDF which permeates the leukocyte membrane to allow fluorescent staining of nucleic acids by fluorocellTM WDF. A semiconductor laser is then used to detect cells by flow cytometry. A combination of side scatter light (SSC), reflecting complexity of intracellular structures, side fluorescence light (SFL), reflecting fluorescence intensity, and forward scatter light (FSC), to measure cell size, is combined by an intelligent gating algorithm provided by 00-19E (Build 2) IPU version software to judge WBC type. The WDF scattergram shows IGs as dark blue dots above neutrophils. The Q-flag represents the healthy maximal limit of IGs and, above this threshold, "IG present" is indicated. Previous studies have reported general evaluation of Sysmex XN performance in measuring IG parameters [15–17], but application of this approach to MNs has been neglected.

The current study aimed to investigate Sysmex XN series performance in IG quantification in various MNs by comparison with manual measurements. Evaluation of the suitability of the Sysmex XN analyzer in reliable detection of IGs in PB and screening for MNs was assessed.

Materials and methods

Blood samples

A total of 1412 blood samples, including 388 from MN patients, 524 from patients with non-hematological neoplasms (non-HNs), and 500 from healthy control subjects, taken between November 2016 and December 2019 in Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, were included in the study.

MN patients were enrolled from the Department of Hematology and diagnosed according to 2016 WHO classification criteria [11, 18]. Specimens were collected at first diagnosis prior to chemotherapy or recurrence. Data from each individual was included in the study only once and MN patients without complete data were excluded. Characteristics of all MN patients are shown in Table 1. Non-HN patients were enrolled from departments other than hematology, including 284 from internal medicine, 177 from surgery, and 63 from ophthalmology, otolaryngology, stomatology, gynecology, neurology, dermatology, or traditional Chinese medicine. Non-HN patients included 109 with inflammation from respiratory medicine, intensive care unit, and rheumatology and surgery department, and 68 undergoing recombinant human G-CSF administration from the oncology department. Healthy individuals were enrolled from the physical examination center with the exclusion of pregnant women.

Anticoagulant PB samples were taken with EDTA (Becton Dickinson, San Jose, USA) for routine blood analysis. The study was approved by the medical Ethics Committee of Shandong Provincial Hospital (No.2016-KY-051).

Sample analysis

The fully automated Sysmex XN series employs the automated hematology analyzer, XN-9000 (Sysmex, Kobe, Table 1 Characteristics of MN patients

Diagnosis	Cases				
AML and related precursor neoplasms					
AML with recurrent genetic abnormalities	83				
AML with RUNX1-RUNX1T1	7				
AML with CBFB-MYH11	10				
Acute promyelocytic leukemia with PML-RARA	42				
AML with mutated NPM1	10				
AML with biallelic mutation of CEBPA	10				
AML with mutated RUNX1	4				
AML with myelodysplasia-related changes	5				
Therapy-related AML	3				
AML, NOS	140				
AML without maturation	6				
AML with maturation	52				
Acute myelomonocytic leukemia	41				
Acute monoblastic and monocytic leukemia	41				
Myeloproliferative neoplasms	77				
CML	47				
Primary myelofibrosis	30				
MDS	63				
Myelodysplastic/myeloproliferative neoplasm	17				
Chronic myelomonocytic leukemia	10				
Myelodysplastic/myeloproliferative neoplasm, unclassifi- able	7				
Total MN	388				

Japan), equipped with 00-19E (Build 2) IPU version and the automated slide making/staining device, Sysmex SP-10 (Sysmex, Kobe, Japan). Annual calibration of the XN analyzer was performed, and precision, linearity, carryover, and stability were evaluated regularly. Measurement uncertainty, the dispersion of the measured value reasonably assigned by the characterization, was 0.03×10^9 /L for IG# from XN, 0.2% for IG% from XN, and 0.8% for IG% from manual methods. Two levels of blood XN checkTM were conducted daily to monitor equipment performance and incorporated into the Sysmex program for real-time quality control. All MN and non-HN PB samples were initially analyzed by XN-9000; blood smears were made and stained using SP-10 and Wright Giemsa (Muto Pure Chemicals, Tokyo, Japan). Control samples were assayed by XN-9000, only, and no blood smears made. All samples were analyzed within 4 h of collection. All threshold values of O-flags ("IG present", "Left shift", "Blast", "Abn lympho", and "Atypical lympho") were set at 100. The WBC#, RBC#, HGB#, PLT#, IG#, IG%, instrument flags, and WDF scattergrams of all samples were recorded.

Two experienced technologists manually classified 200 cells per smear using an Olympus BX53 microscope according to the Clinical and Laboratory Standards Institute (CLSI) H20-A2 [19]. The mean IG%, composed of promyelocytes, myelocytes, and metamyelocytes, calculated by the 2 technologists was considered to be the final result. In the event of significant differences between the results from the 2 technologists, a third technologist classified the slide.

Statistical analysis

Non-parametrical tests (Mann-Whitney test) were performed to compare IG parameters between 2 different groups and the Kruskal-Wallis test to compare 3 or more groups. Spearman rank correlation coefficient analysis was used to evaluate the relationship between IG% values obtained from the Sysmex XN analyzer and from manual assessment. Values for r coefficients < 0.30 were considered to present negligible correlations; 0.30-0.50 low correlations; 0.50-0.70 moderate correlations; 0.70–0.90 strong correlations; and \geq 0.90 a very high correlation [20]. Bland–Altman bias analysis was performed to compare IG% differences from the two methods. Receiver operating characteristic (ROC) curve analysis was conducted to estimate sensitivity, specificity, and cut-off value for IG parameters assayed by XN analyzer. Pairwise comparisons of the area under the ROC curves (AUCs) were performed using Z-test.

MedCalc Software 19.1 (Ostend, Belgium) and IBM SPSS Statistics 18.0.0 (Chicago, USA) were used. A value of p < 0.05 was considered to be statistically significant.

Results

Comparison of XN-derived IG# and IG% values and manually-derived IG% in PB from MN, non-HN and control subjects

Increased IG# (both p < 0.0001) and IG% (both p < 0.0001) from XN series measurements were observed in MN and non-HN patients when compared with healthy controls (Fig. 1). IG% in healthy controls was not analyzed manually as the positive ratios were too low. Subgroups of patients with inflammation and receiving G-CSF showed higher levels of IG# and IG% from XN analysis plus IG% from manual measurements than the entire group of non-HN patients (all p < 0.0001; Fig. 1). Subgroups of MN patients with MPN (CML and PMF) showed the highest levels of XN-derived IG# and IG% values and also IG% from manual measurements (all p < 0.0001) when compared with other subgroups (Fig. 1).

Correlations and differences between XN and manual estimates of IG% in MN and non-HN patients

Strong correlations between XN- and manually derived IG% values were found in both MN and non-HN patients



Fig. 1 Comparison of IG#-XN, IG%-XN and IG%-manual values across groups. Columns and bars represent median with interquartile range

Table 2 Spearman rank correlation analysis of XN- and manually derived IG% values in PB from MN and non-HN patients

	N	Correlation coef- ficient (r)	p value
Non-HN	524	0.861	< 0.0001
Inflammation	109	0.717	< 0.0001
G-CSF	68	0.762	< 0.0001
MN	388	0.828	< 0.0001
AML	231	0.597	< 0.0001
MPN	77	0.873	< 0.0001
MDS	63	0.767	< 0.0001
MDS/MPN	17	0.750	0.0005

(Table 2). Although correlations were statistically significant in all groups of patients with AML, MPN, MDS, and MDS/ MPN, only moderate correlations were shown for AML patients (Table 2).

Differences between XN- and manually derived IG% values were compared using Bland–Altman bias analysis, and differences for both MN and non-HN patients were considered clinically insignificant (Fig. 2). However, a relatively high difference in the mean and in the 95% CI of limits of agreement (LoA) was shown in the G-CSF subgroup (Fig. 2).

Analysis of ROC curve and cut-off values of XN IG# and IG% from MN and non-HN patients

ROC analysis was performed to assess XN-derived values of IG# and IG% in detection of IGs in PB. IG% values from manual inspection were regarded as the gold standard against which the IG# and IG% values from XN measurements were compared. The AUCs of XN-derived IG# and IG% values were above 0.8 for both MN and non-HN patients, indicating a good level of detection (Table 3).



Fig. 2 Comparison of XN- and manually-derived IG% values using Bland–Altman plot. The difference between two values (XN IG% – manual IG%) was plotted on the y-axis against manual IG% on the x-axis. Solid lines: mean differences; dashed lines: mean difference ± 1.96 SD

Comparison of the AUCs for XN-derived IG# and IG% values for MN patients revealed that the IG% values showed better efficiency than IG# (p < 0.05). Both the XN-derived IG# and IG% parameters showed higher efficiency in non-HN than in MN patients (p < 0.05). The Youden index gave cut-off values of 0.200×10^9 /L for IG# and 1.95% for IG% (Table 3).

Discussion

IGs are often found in the PB of patients with acute infection, inflammation, acute hemorrhage, and those receiving G-CSF. The non-HN patients enrolled in the current study included a number of patients with these conditions accounting for the finding that IG levels among non-HN patients were higher than those of controls.

IGs are easily distinguishable from mature leukocytes in the WDF channel due to their larger nuclear volume and higher fluorescent intensity. This observation underlies the strong correlations between IG% values measured by XN and those from manual inspection in non-HN and MN PB samples. However, morphological abnormalities of immature and mature granulocytes confuse the identification of IGs, resulting in inaccurate counts.

Overall comparisons of WDF scattergrams revealed that inconsistencies between IG% values from XN and manual measurements were usually due to inaccurate IG gating in the scattergram (Supplemental Fig. S1). Granulocytes with morphological abnormalities could be identified in blood smears from all of the inconsistent cases (Supplemental Fig. S2). This phenomenon was observed among samples from patients with acute promyelocytic leukemia (APL), acute myelomonocytic leukemia (AML-M4), and acute monoblastic and monocytic leukemia (AML-M5). The 2015 International Council for Standardization in Haematology (ICSH) recommended that abnormal promyelocytes in APL samples should be counted as blast equivalents rather than as IGs [1]. In addition, neutrophil dysplasia, such as hypogranulation and hyposegmentation, may also be present in AML samples [1, 11] and might interfere with IG gating, leading to inconsistencies. Moreover, "left shift", arising from elevation of percentages of band neutrophils (>5%)and cells with hypergranulation, vacuolation, and cytosolic Döhle bodies [1, 21], often follows G-CSF administration and may interfere with the intelligent software system gating and falsely raise IG count.

Table 3 ROC curve and cut-off values for XN-derived IG# and IG% values in PB from MN and non-HN patients

	N	AUC	SE	95% CI ^a	p value	Cut-off	Sensitivity	Specificity	Youden index
IG#-XN,×10 ⁹ /L						0.200			
Non-HN	524	0.918	0.013	0.892 to 0.943	< 0.0001		0.767	0.886	0.653
MN	388	0.842	0.002	0.803 to 0.881	< 0.0001		0.746	0.791	0.537
IG%-XN, %						1.95			
Non-HN	524	0.937	0.011	0.916 to 0.958	< 0.0001		0.787	0.934	0.721
MN	388	0.885	0.017	0.851 to 0.918	< 0.0001		0.813	0.784	0.597

In summary, the IG parameters derived from Sysmex XN hematology analyzer efficiently indicate the presence of IG in PB of MN patients, and this approach may facilitate screening for MNs. In addition, inaccuracies in XN-derived IG parameter measurements may arise due to the presence of granulocytes with morphological abnormalities in PB samples.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12308-022-00484-w.

Acknowledgements The authors would like to express their gratitude to EditSprings (https://www.editsprings.cn/) for the expert linguistic services provided.

Author contribution Yajuan Shen conceptualized, designed, and supervised the study and also drafted the manuscript; Qifeng Lu analyzed data and edited the manuscript; Tian Li and Tingting Hou provided interpreting data; Ying Li participated in discussing the conception and manuscript; Yajuan Zhao, Shu Feng, Xixian Yang, and Mengyu Zhu sorted out data.

Funding This work was supported by Natural Science Foundation of Shandong Province, China, under Grant (No.ZR2017MH088).

Availability of data and material Available on request.

Declarations

Ethics approval This study was approved by the medical Ethics Committee of Shandong Provincial Hospital (No.2016-KY-051).

Consent to participate This study was conducted only after taking informed consent from all participants.

Consent for publication All the authors gave their consent for submission/publication of this manuscript.

Conflict of interest The authors declare no competing interests. $95\% CI^a 95\%$ confidence intervals.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Palmer L, Briggs C, McFadden S, Zini G, Burthem J, Rozenberg G et al (2015) ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features. Int J Lab Hematol 37:287-303

- Fowlie PWSB (1998) Diagnostic tests for bacterial infection from birth to 90 days–a systematic review. Arch Dis Child Fetal Neonatal Ed 78:F92-98
- Fernández-Suárez APV, Gimenez MT, Hernández JF (2003) Immature granulocyte detection by the SE-9000 haematology analyser during pregnancy. Clin Lab Haematol 25:347–351
- Blazkova J, Gupta S, Liu Y, Gaudilliere B, Ganio EA, Bolen CR et al (2017) Multicenter systems analysis of human blood reveals immature neutrophils in males and during pregnancy. J Immunol 198:2479–2488
- Nigro KG, O'Riordan M, Molloy EJ, Walsh MC, Sandhaus LM (2005) Performance of an automated immature granulocyte count as a predictor of neonatal sepsis. Am J Clin Pathol 123:618–624
- Cimenti C, Erwa W, Herkner KR, Kasper DC, Muller W, Resch B (2012) The predictive value of immature granulocyte count and immature myeloid information in the diagnosis of neonatal sepsis. Clin Chem Lab Med 50:1429–1432
- Karon BS, Tolan NV, Wockenfus AM, Block DR, Baumann NA, Bryant SC et al (2017) Evaluation of lactate, white blood cell count, neutrophil count, procalcitonin and immature granulocyte count as biomarkers for sepsis in emergency department patients. Clin Biochem 50:956–958
- Yoo J, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW (2018) Delta neutrophil index is associated with vasculitis activity and risk of relapse in ANCA-associated vasculitis. Yonsei Med J 59:397–405
- 9. Zhong H, Yazdanbakhsh K (2018) Hemolysis and immune regulation. Curr Opin Hematol 25:177–182
- Park SH, Park CJ, Kim MJ, Han MY, Lee BR, Cho YU et al (2016) Evaluation of parameters obtained from the Sysmex XN-2000 for predicting the recovery of the absolute neutrophil count and platelets after hematopoietic stem cell transplantation. Int J Lab Hematol 38:198–208
- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
- 12. Carulli G (1997) Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions. Haematologica 82:606–616
- Vadhan-Raj SKM, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE et al (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552
- Field D, Taube E, Heumann S (2006) Performance evaluation of the immature granulocyte parameter on the Sysmex XE-2100 automated hematology analyzer. Lab Hematol 12:11–14
- Seo JY, Lee ST, Kim SH (2015) Performance evaluation of the new hematology analyzer Sysmex XN-series. Int J Lab Hematol 37:155–164
- Redin ME, Vives A, Garrido A, Urrechaga E, Lacasta M (2016) Local verification between the hematological analyzers Sysmex XN-series and XE-5000. Int J Lab Hematol 38:256–264
- Schoorl M, Schoorl M, Chevallier M, Urrechaga E, Lacasta M (2017) Multicenter verification of the Sysmex XN-Series. Int J Lab Hematol 39:489–496
- Swerdlow SH, Campo E, Pileri SA, Stein H, Siebert R, Advani R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390
- Clinical Laboratory Standards Institute (2007) Reference leukocyte (WBC) differential count (proportional) and evaluation of instrumental methods; approved standard, 2nd edn, Wayne, CLSI

- Mukaka MM (2012) Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24:69–71
- 21. Prokocimer M, Potasman I (2008) The added value of peripheral blood cell morphology in the diagnosis and management of infectious diseases–part 1: basic concepts. Postgrad Med J 84:579–585
- 22. Maenhout TM, Marcelis L (2014) Immature granulocyte count in peripheral blood by the Sysmex haematology XN series compared to microscopic differentiation. J Clin Pathol 67:648–650
- Briggs CJ, Linssen J, Longair I, Machin SJ (2011) Improved flagging rates on the Sysmex XE-5000 compared with the XE-2100 reduce the number of manual film reviews and increase laboratory productivity. Am J Clin Pathol 136:309–316

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.